Johnson & Johnson JNJ

$261.44 +4.96 (1.93%)

Valuation

Market cap
630,043,712,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.62
Forward PE
22.95
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
5,727,200
Avg volume
6,565,684
Day's range
$254.99 – $261.61
Shares out
2,409,898,000
Stochastic %K
50%
Beta
0.21
Analysts
Strong Sell
Price target
$282.76

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Investor203 Oct 11, 10:47 PM
$JNJ BO offer to $VNDA $20 or $2. Lol. Come on
0 replies
WW789 Oct 11, 10:31 PM
$SLS GPS/009 👊 1-2 combo $JNJ
1 replies
DarkH0rse91 Oct 11, 10:23 PM
$SLS $JNJ This is how ASH board is probably gonna look like
0 replies
Gfywoody Oct 11, 10:16 PM
$JNJ Trending from 5 posts today? One Ai pic I stole from a Sellas homie, reshared 2 times, eyeballs 👀, and a comment about earnings Tuesday. What kind of scam site is this? 🤣 Oh 40 Billy buyout or bust.
0 replies
AccessATrader Oct 11, 10:12 PM
Risk & Discipline If you want to jump out of a window, don't you want to jump out from the 1st floor, not the 10th floor? Window-jump analogy for cutting losses early. — Dan Shapiro $NVDA $TSLA $SLS $VELO $JNJ
0 replies
KryptonResearch14 Oct 11, 9:58 PM
$JNJ J&J reports Tuesday before the open. Consensus EPS fell about 17% over the summer (3.03 to 2.51), then got raised back about 4% in the last 30 days (2.42 to 2.51), per AlphaStreet. The last four quarters all beat. In July they beat 2.90 to 2.84 and the stock still sold off 2.7% that day. Friday close 261.44, about 7% below the September 2 peak. 23.3x forward non-GAAP earnings vs 18.7x for the industry (Barchart).
0 replies
Bungfolio Oct 11, 9:57 PM
$SLS 5:57, looks like we bumped $JNJ to #2
0 replies
Stonker39 Oct 11, 9:51 PM
$SLS and $JNJ trending #1 and #2 😀
0 replies